论文部分内容阅读
为探讨儿童非霍奇金淋巴瘤的治疗策略和合理治疗方法。按临床分期不同采用以ＣＯＰＰ，ＣＨＯＰ和ＢＡＣＯＰ方案为主的联合化疗或联合放疗的综合治疗方法。９０例儿童非霍奇金淋巴瘤，按ＡｎｎＡｒｂｏｒ临床分期，Ⅰ，Ⅱ，Ⅲ，Ⅳ期分别有１１例，３５例，１２例，３２例，其中３０例有全身症状。中、高度恶性分别有５７例和３１例，未分型２例。治疗后全组近期疗效为完全缓解（ＣＲ）５４例，部分缓解（ＰＲ）１５例，稳定（Ｓ）１例，进展（Ｐ）２０例，其中ＣＲ病例包括手术切除肿块的６例。全组的治疗后１，３，５ａ和１０ａ生存率分别为６３．３％，３８．５％，３８．５％和３４．５％。通过对不同临床分期，不同临床病理分型，有无全身症状，不同近期疗效者与治疗后长期生存率关系的分析显示，Ⅰ，Ⅱ期的长期生存率优于Ⅲ，Ⅳ期，中度恶性者优于高度恶性，无全身症状者优于有全身症状者，治疗后肿瘤完全缓解者优于部分缓解、稳定或进展的病例。结果提示，通过综合治疗，争取首程治疗达到肿瘤完全缓解是提高儿童非霍奇金淋巴瘤远期生存率的主要策略之一。
To explore the treatment of non-Hodgkin’s lymphoma in children and reasonable treatment methods. According to different clinical stages with COPP, CHOP and BACOP program-based combination chemotherapy or combined radiotherapy treatment. 90 cases of children with non-Hodgkin’s lymphoma, Ann Arbor clinical stage, Ⅰ, Ⅱ, Ⅲ, Ⅳ were 11 cases, 35 cases, 12 cases, 32 cases, of which 30 cases had systemic symptoms. 57 cases and 31 cases were highly malignant, respectively, and 2 cases were untreated. The complete course of treatment was 54 cases of complete remission (CR), 15 cases of partial remission (PR), 1 case of stable (S) and 20 cases of progression (P). Among them, 6 cases were CR cases including resection of tumor. The 1, 3, 5a and 10a survival rates were 63.3%, 38.5%, 38.5% and 34.5%, respectively, in the whole group. Through the analysis of the relationship between different clinical stages, different clinical pathological types, with or without systemic symptoms, different short-term effects and long-term survival after treatment, the long-term survival rates of stage Ⅰ and Ⅱ were better than those of stage Ⅲ and Ⅳ, Those who were superior to highly malignant and without systemic symptoms were better than those with systemic symptoms. Patients with complete remission after treatment were better than those with partial remission, stable or progression. The results suggest that, through comprehensive treatment, fight for the first stroke treatment to achieve complete tumor remission is to improve the long-term survival of children with non-Hodgkin’s lymphoma, one of the main strategies.